Comedian and activist joins Google Ventures, 5AM Ventures, Transformation Capital and G9 Ventures to set a new standard in infertility treatment
NEW YORK, Dec. 1, 2022 /PRNewswire/ — TMRW Life Sciences, Inc. (TMRW), creator of the world's first and only software-based automated sample management platform for frozen eggs and embryos used for intravenous fertilization vitro (IVF), announced today that award-winning actress, New York Times bestselling author and IVF patient author Amy Schumer becomes a new investor in TMRW.
"I'm very grateful to be a mom, but it's a long and difficult process," said Schumer, who spoke about her experiences with hyperemesis gravidarum, endometriosis and IVF. “When I went through the IVF procedure, it was physically and emotionally draining and there was a lot of uncertainty. It never occurred to me to ask how my embryos were handled and stored. That is why I am proud to invest in TMRW. Their technology lab is transforming the fertility industry by making processes safer and more transparent so patients have one less problem to worry about.”
Since the introduction of human IVF over 40 years ago, significant advances in treatment have been made; However, the organization and handling of frozen oocytes and embryos remain largely unchanged. Embryologists still perform manual tasks, which are time-consuming and often error-prone, primarily using small handwritten labels and paper journals. By deploying TMRW's unique digital supply chain and technology platform, physicians and patients gain unprecedented visibility, security, and peace of mind, freeing physicians to focus on what they do best: raising families.
“Patients are becoming more educated and informed about how their frozen eggs or embryos will be handled when undergoing IVF or egg freezing. As an IVF mom, I know firsthand the comfort that more information and transparency brings,” said Tara Komont, Executive Director of TMRW. “Our technology is designed with security and transparency in mind, allowing clinicians and patients to be continuously monitored, managed and stored. These are precious frozen eggs and embryos. possible; We are proud to have him join us on this mission."
TMRW Life Sciences has developed the only FDA-cleared automated solution that digitally monitors and manages frozen eggs and embryos used in IVF. The TMRW platform has been adopted by world-renowned clinics across the country, including Vios Fertility/Kindbody, Boston IVF, CCRM Fertility; San Diego Center for Reproductive Medicine, Colorado Reproductive Technology Association, Institute of Reproductive Medicine and Science, and RMA New York .
TMRW's integrated software and hardware systems for clinics and patients usher in a new era of infertility treatment where advanced technology and automation are the norm, not the exception.
About TMRW Life Sciences, Inc.
Founded in 2018, TMRW Life Sciences, Inc. is a life sciences technology company committed to safety and transparency in IVF modernization and transformation. For the first time, frozen eggs and embryos can be digitally identified and tracked, safely handled with automated robotics, and remotely monitored 24/7. With proprietary RFID-enabled lab equipment and an integrated software management solution, TMRW protects life's most valuable cells. Named by Fast Company as the Most Innovative Biotech Company of 2022, TMRW has been adopted by leading clinics in the US and will soon be available in the UK and Europe. With continued significant growth in fertility services and an expected increase in IVF births, TMRW provides a scalable solution for clinics, bringing frozen embryo and egg care into the 21st century. For more information, visit www.tmrw.org .
contacts:
by Jessica Baltera
jbaltera@tmrw.org
View original content: https://www.prnewswire.com/news-releases/womens-health-advocate-amy-schumer-joins-tmrw-life-sciences-as-investor-301691600.html
formula